Ihuman Inc Stock Current Valuation
| IH Stock | USD 1.55 0.09 5.49% |
Valuation analysis of Ihuman Inc helps investors to measure Ihuman's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of now, Ihuman's Enterprise Value Over EBITDA is increasing as compared to previous years. The Ihuman's current Enterprise Value Multiple is estimated to increase to 0.05, while Enterprise Value is projected to decrease to under 7.5 M. Fundamental drivers impacting Ihuman's valuation include:
Price Book 0.684 | Enterprise Value -69.7 M | Enterprise Value Ebitda 0.7528 | Price Sales 0.0893 | Forward PE 58.1395 |
Undervalued
Today
Please note that Ihuman's price fluctuation is very risky at this time. Calculation of the real value of Ihuman Inc is based on 3 months time horizon. Increasing Ihuman's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ihuman is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ihuman Stock. However, Ihuman's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.55 | Real 2.08 | Target 3.78 | Hype 1.55 | Naive 1.54 |
The intrinsic value of Ihuman's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Ihuman's stock price.
Estimating the potential upside or downside of Ihuman Inc helps investors to forecast how Ihuman stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ihuman more accurately as focusing exclusively on Ihuman's fundamentals will not take into account other important factors: Ihuman Inc Company Current Valuation Analysis
Ihuman's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ihuman Current Valuation | (69.71 M) |
Most of Ihuman's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ihuman Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ihuman Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Ihuman is extremely important. It helps to project a fair market value of Ihuman Stock properly, considering its historical fundamentals such as Current Valuation. Since Ihuman's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ihuman's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ihuman's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ihuman Inc has a Current Valuation of (69.71 Million). This is 100.36% lower than that of the Hotels, Restaurants & Leisure sector and 102.74% lower than that of the Consumer Discretionary industry. The current valuation for all United States stocks is 100.42% higher than that of the company.
Ihuman Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ihuman's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ihuman could also be used in its relative valuation, which is a method of valuing Ihuman by comparing valuation metrics of similar companies.Ihuman is currently under evaluation in current valuation category among its peers.
Ihuman Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ihuman from analyzing Ihuman's financial statements. These drivers represent accounts that assess Ihuman's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ihuman's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 5.0B | 5.4B | 941.4M | 955.9M | 1.2B | 1.2B | |
| Enterprise Value | 4.9B | 4.5B | 120.3M | (85.0M) | 7.9M | 7.5M |
Ihuman Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | (69.71 M) | ||||
| Shares Outstanding | 23.57 M | ||||
| Shares Owned By Institutions | 0.61 % | ||||
| Number Of Shares Shorted | 4.44 K | ||||
| Price To Earning | 7.83 X | ||||
| Price To Book | 0.68 X | ||||
| Price To Sales | 0.09 X | ||||
| Revenue | 1.02 B | ||||
| Gross Profit | 660.62 M | ||||
| EBITDA | 171.58 M | ||||
| Net Income | 180.91 M | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 16.08 X | ||||
| Total Debt | 3.86 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 2.27 X | ||||
| Book Value Per Share | 17.36 X | ||||
| Cash Flow From Operations | 172.12 M | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 3.86 | ||||
| Number Of Employees | 783 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 85.89 M | ||||
| Total Asset | 1.45 B | ||||
| Retained Earnings | (140.46 M) | ||||
| Working Capital | 891.68 M | ||||
| Annual Yield | 0.06 % | ||||
| Net Asset | 1.45 B |
About Ihuman Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ihuman Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ihuman using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ihuman Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Ihuman Piotroski F Score and Ihuman Altman Z Score analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Hotels, Restaurants & Leisure space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ihuman. If investors know Ihuman will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ihuman listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.16) | Revenue Per Share 18.263 | Quarterly Revenue Growth (0.11) | Return On Assets 0.0456 |
The market value of Ihuman Inc is measured differently than its book value, which is the value of Ihuman that is recorded on the company's balance sheet. Investors also form their own opinion of Ihuman's value that differs from its market value or its book value, called intrinsic value, which is Ihuman's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ihuman's market value can be influenced by many factors that don't directly affect Ihuman's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ihuman's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ihuman is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ihuman's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.